IRF8 and B-cell non-Hodgkin lymphoma: Therefore, we decided to examine whether the IRF8 mutant–associated remodeling of the TME and attendant growth advantage that we detected in B cell lymphoma models, was still amenable to correction with checkpoint inhibitors of the PD-1/PD-L1 pathway.